Private Wealth Partners LLC Boosts Stock Position in Eli Lilly and Company (NYSE:LLY)

Private Wealth Partners LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 31.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 4,730 shares of the company’s stock after purchasing an additional 1,145 shares during the period. Private Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $2,757,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Valmark Advisers Inc. lifted its holdings in Eli Lilly and Company by 1.5% in the fourth quarter. Valmark Advisers Inc. now owns 4,543 shares of the company’s stock worth $2,648,000 after buying an additional 69 shares during the period. Gilliland Jeter Wealth Management LLC purchased a new stake in Eli Lilly and Company in the fourth quarter worth about $673,000. Terril Brothers Inc. lifted its holdings in Eli Lilly and Company by 113.2% in the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after buying an additional 429 shares during the period. Headlands Technologies LLC lifted its holdings in Eli Lilly and Company by 82.7% in the fourth quarter. Headlands Technologies LLC now owns 3,710 shares of the company’s stock worth $2,163,000 after buying an additional 1,679 shares during the period. Finally, Citizens Financial Group Inc. RI lifted its holdings in Eli Lilly and Company by 3.2% in the fourth quarter. Citizens Financial Group Inc. RI now owns 39,259 shares of the company’s stock worth $22,885,000 after buying an additional 1,227 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on LLY. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. BMO Capital Markets raised their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Bank of America lifted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $8.64 during trading hours on Friday, reaching $733.51. The company had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52 week low of $380.77 and a 52 week high of $800.78. The firm has a market cap of $696.95 billion, a price-to-earnings ratio of 126.47, a PEG ratio of 1.60 and a beta of 0.34. The firm’s 50 day moving average price is $761.79 and its 200-day moving average price is $666.67.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the previous year, the firm posted $2.09 EPS. The firm’s revenue was up 28.1% on a year-over-year basis. On average, analysts forecast that Eli Lilly and Company will post 12.51 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.